Navigant Consulting (NCI) Reports In-Line Q1 EPS, Beats on Revenues; FY18 EPS Mid-Point Guidance Above Consensus, FY18 Revenue Outlook Above Consensus

Navigant Consulting (NYSE: NCI) reported Q1 EPS of $0.30, in-line with the analyst estimate of $0.30. Revenue for the quarter came in at $264.5 million versus the consensus estimate of $239.34 million.

First quarter 2018 financial summary:

• Revenues and revenues before reimbursements (RBR) of $264.5 million and $243.9 million, respectively were both up 3% compared to first quarter 2017
• Net income was $11.9 million, or $0.25 per share, compared to $11.1 million, or $0.23 per share, for first quarter 2017
• Adjusted Earnings per Share (EPS) of $0.30 increased $0.03 compared to first quarter 2017
• Repurchased $11.4 million of common stock in the quarter, significantly higher than the $5.0 million repurchased in the prior year period
• Management affirms previously provided 2018 financial guidance targets

2018 OUTLOOK

Management affirms full year 2018 financial outlook as originally communicated on February 20, 2018:

• Total revenues estimated to be between $1.030 billion and $1.065 billion
• RBR expected to range between $940 million and $975 million
• Adjusted EBITDA expected to range between $125 million and $137 million
• Adjusted EPS estimated to be between $1.26 and $1.44
• Capital expenditures estimated to be approximately $25 million
• Free Cash Flow expected to range between $75 million and $90 million

GUIDANCE:

Navigant Consulting sees FY2018 EPS of $1.26-$1.44, versus the consensus of $11.30. Navigant Consulting sees FY2018 revenue of $1.03-1.065 billion, versus the consensus of $949.16 billion.

For earnings history and earnings-related data on Navigant Consulting (NCI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c